| Dr Jason Jer Jai Chang, MD | |
|
125 16th Ave E, Seattle, WA 98112-5211 | |
| (206) 326-3000 | |
| Not Available |
| Full Name | Dr Jason Jer Jai Chang |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 17 Years |
| Location | 125 16th Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366649840 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Medical Center / Cherry Hill | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.
Induced pluripotent stem cells hold promise for regenerative medicine because they can, in theory, turn into any type of tissue and because they are made from a patient's own adult cells, guaranteeing compatibility. However, the technique that turns adult cells into these iPS cells is not foolproof; after reverting to their pluripotent state, these cells don't always correctly differentiate back into adult cells.
› Verified 7 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.
Induced pluripotent stem cells hold promise for regenerative medicine because they can, in theory, turn into any type of tissue and because they are made from a patient's own adult cells, guaranteeing compatibility. However, the technique that turns adult cells into these iPS cells is not foolproof; after reverting to their pluripotent state, these cells don't always correctly differentiate back into adult cells.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Jer Jai Chang, MD 125 16th Ave E, Seattle, WA 98112-5211 Ph: (503) 418-9888 | Dr Jason Jer Jai Chang, MD 125 16th Ave E, Seattle, WA 98112-5211 Ph: (206) 326-3000 |
News Archive
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.
Induced pluripotent stem cells hold promise for regenerative medicine because they can, in theory, turn into any type of tissue and because they are made from a patient's own adult cells, guaranteeing compatibility. However, the technique that turns adult cells into these iPS cells is not foolproof; after reverting to their pluripotent state, these cells don't always correctly differentiate back into adult cells.
› Verified 7 days ago
George A Ojemann, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-5637 | |
Mr. Trent Lane Tredway, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 737 Olive Way Apt 2502, Seattle, WA 98101 Phone: 206-623-1334 Fax: 206-623-1677 | |
Daniel A Lazar, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1560 N 115th St, 209, Seattle, WA 98133 Phone: 206-368-1701 Fax: 206-363-0019 | |
Mohammed Basamh, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 550 17th Ave Ste 500, Seattle, WA 98122 Phone: 206-320-2451 | |
Dr. Christoph Paul Hofstetter, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Campus Box 356470, Room Rr734, Seattle, WA 98195 Phone: 507-202-9523 | |
David Keisho Su, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 900 Lenora St, 501, Seattle, WA 98121 Phone: 559-260-0047 | |
Syed Shabaz Azeem, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 16th Ave E, Seattle, WA 98112 Phone: 206-326-3000 |